Results 231 to 240 of about 263,171 (350)

The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials. [PDF]

BJPsych Open
Trott M, Arnautovska U, Johnston D, Ritchie G, Siskind D.   +4 more
europepmc   +1 more source

THE NEW PARADIGM OF RECOVERY FROM SCHIZOPHRENIA: CULTURAL CONUNDRUMS OF IMPROVEMENT WITHOUT CURE [PDF]

, 2006
CARPENTER-SONG, ELIZABETH, JENKINS, JANIS H   +1 more
core  

Electroconvulsive Therapy and Time to Psychiatric Readmission in Schizophrenia

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction There is evidence that electroconvulsive therapy (ECT) can augment the effects of antipsychotics in schizophrenia. However, there is limited evidence from Western populations on whether ECT reduces the risk of relapse compared to non‐ECT treatment in schizophrenia.
Linnea Stenmark, Mussie Msghina, Axel Nordenskjöld   +2 more
wiley   +1 more source

Trends in use of antipsychotics in Germany 2014-2024: a nationwide population-based study. [PDF]

BMC Psychiatry
Espinosa Daudí A, Kieble M, Schulz M.
europepmc   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Development of a patient decision aid prototype on the decision to continue, reduce or discontinue antipsychotic medication following remission of first-episode psychosis. [PDF]

BJPsych Open
Béchard L, Corbeil O, Huot-Lavoie M, Roy O, Brodeur S, Bouchard E, Martel J, Pavey N, Achim AM, Menear M, Roy MA, Lauzier S, Demers MF.   +12 more
europepmc   +1 more source

Antipsychotic Use in Dementia

Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2017
J. Kirkham, Chelsea Sherman, Clive Velkers, C. Maxwell, S. Gill, P. Rochon, D. Seitz   +6 more
semanticscholar   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source